Pharmasyntez JSC

SIBUR and the biopharmaceutical company Pharmasyntez have agreed to jointly develop and supply synthetic materials for the new production facility for hemodialysis and peritoneal dialysis consumables and equipment, which is scheduled to be commissioned in Kaluga Oblast in 2025.   Against the backdrop of the withdrawal of one of the largest suppliers of dialysate from the Russian market, Pharmasyntez and SIBUR have developed solutions in the shortest possible time to maintain technological sovereignty and further develop the Russian pharmaceutical industry. SIBUR will supply polymer materials such as polypropylene and polyethylene for Pharmasyntez's new production.   In addition, for the production of dialyzer housings, SIBUR is developing a special grade of polycarbonate compatible with radiation sterilization, an important step in creating domestically produced world-class medical products. The development and testing of the formulation is expected to be completed in 2025.   Pharmasyntez has successfully used the medical grade polyethylene MG 013 developed by SIBUR for packaging infusion solutions by the blow-fill-seal (BFS) method as part of the company's import substitution strategy at its Irkutsk plant.   Anton Prozumentov, Director of Sibur's Pharmaceuticals Department, said: "Development of the Russian pharmaceutical industry is one of the important areas of ensuring the country's technological independence. We actively support efforts to replace imports, especially in strategically important sectors such as medicines. SIBUR attaches great importance to the development and implementation of high-tech solutions to create high-quality, reasonably priced products that replace imported analogues and meet the domestic needs of the Russian market."

俄中药物研究论坛2024即将于6月20日在上海召开。此次活动将汇集俄罗斯联邦工业和贸易部、中国监管机构和俄罗斯卫生部等部门的杰出代表，共同探讨药物研发的未来趋势，分享临床经验，并加强两国在药品进出口等领域的战略合作。俄中药物研究论坛已成为中俄两国在医药领域合作的重要基石，旨在推动双方在医药领域的全面合作与发展。 此次俄中药物研究论坛涵盖丰富及广泛的主题议程，核心目标聚焦于深化双边合作，以推动俄罗斯与中国制药行业的蓬勃发展。沿袭往届论坛的传统，本次盛会将继续安排多场专题会议，届时将重点探讨行业内的战略规划和实际挑战，例如： 俄罗斯药品营销授权解析； 临床试验立法规范梳理； 当地药品技术需求洞察； 生物技术合作强化策略； 高级治疗药品挑战与前景； 创新药物与疫苗开发合作机遇； GMP检查标准解读； 药品进出口动态与物流优化； 海外制药市场商业价值探讨。 关键发言人 Ekaterina Prieszheva 俄罗斯联邦工业和贸易部副部长 Alla Trapkova 俄罗斯卫生部医药产品专家评估科学中心副总经理，生物科学博士 Victoria Galkovskaya 联邦知识产权局副局长 Kirill Kaem 斯科尔科沃基金会创新副主席、首席董事总经理 Roman Ivanov 天狼星科技大学转化医学科学中心主任，科技发展副校长 Eugenia Radkova OCT俄罗斯MedSci咨询和卓越TM部门负责人，医学博士，博士生导师 此外，本次论坛荣幸地吸引了来自中国医药工业协会，以及中国和俄罗斯众多知名制药公司和合同研究公司的代表共同参与。发言嘉宾名单正在持续更新中，如需获取最新信息，敬请关注论坛的官方网站。 去年的论坛盛况空前，吸引了超过500名与会者，并得到了电视等媒体的广泛报道，取得了显著成功。闭幕式上，俄罗斯和中国制药公司更是签署了一系列双边合作协议，标志着两国制药行业合作的进一步深化。此外，上一届论坛还见证了俄罗斯在中国设立子公司的里程碑事件，进一步加强了中俄之间的商业联系与合作。 中国制药公司可免费参加此次论坛活动。仅需在点击【阅读原文】，在论坛官方网站中填写报名表格进行预注册即可。   该活动的主要合作伙伴包括 Pharmasyntez Group 和 Nanolek 等俄罗斯领先的制药商。官方合作伙伴包括上海鲁肯工程技术有限公司、PharmEco、JSC Avexima 和 NIOPIK 等公司。 适合参会的受众群体：制药高管、研发公司授权代表、监管机构、科学官员、临床运营、行业决策者、药品经销商和市场准入公司。 时间：6月20日 9:30-13:00 地点：上海浦东嘉里大酒店 地址：世纪公园花木路1388号（距离CPHI展馆步行只需5分钟，CPHI参会者可轻松抵达） 项目详情请至本网站查看:  https://rcprf2024.oct-rus.ru/cn

In an effort to support Venezuela’s vaccination efforts, the first 50 of 100 freezer kits were delivered to the country Wednesday, the United Nations Children’s Fund told Reuters. Health minister Carlos Alvarado said earlier this week that the country has received 1.48 million vaccine doses between China’s Sinopharm and the Russian Sputnik V. Both vaccines require 2 shots. The freezers are vital to the storage of vaccines, particularly because the country’s hospital network often lacks electricity. Venezuela has reported 201,807 infections and 2,208 deaths from Covid-19 since the pandemic started last March, but academics say the number of cases and death toll is much higher. Each refrigerator has a 256-liter capacity and can hold 8,500 doses, Reuters reports. UN chief weighs in on IP debate United Nations chief Antonio Guterres has taken a stance on whether vaccine makers should allow other companies to produce versions of their Covid-19 shot. Guterres supports the sharing of intellectual property, Reuters reports. “The Secretary-General has often called for technology transfers and sharing of know-how and voluntary licensing or sharing of licensing,” spokesman Stephane Dujarric told Reuters. The chief has long called for the vaccines to be made available to all countries, and has asked for more funding for the COVAX sharing facility. The news comes in the same week that Gilead has sued the Russian government for allowing another company to make its remdesivir treatment for patients with Covid-19, according to filings. The filing accuses The Pharmasyntez Company of using Gilead’s process for manufacturing remdesivir without the consent of the patent holder. US President Joe Biden’s administration weighed in on the matter Wednesday, as it came out in support of waiving intellectual property protections in an effort to slow rapid increase in cases in India and South America.